Pricing Zolgensma – the world’s most expensive drug

Pricing Zolgensma – the world’s most expensive drug

Bibliographic Details
Main Author:	Mark Nuijten
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Series:	Journal of Market Access & Health Policy
Subjects:	price valuation reimbursement orphan disease
Online Access:	http://dx.doi.org/10.1080/20016689.2021.2022353

Similar Items

Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020-01-01)

Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)

Analysing criteria for price and reimbursement of orphan drugs in Spain
by: Xavier Badia, et al.
Published: (2019-07-01)

An integrated valuation model for payer and investor
by: Mark Nuijten, et al.
Published: (2022-12-01)

Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
by: Szczepan Jakubowski, et al.
Published: (2024-03-01)

Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries
by: Szczepan Jakubowski, et al.
Published: (2024-11-01)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
by: Konstantin Tachkov, et al.
Published: (2021-01-01)

The length of price&reimbursement negotiation procedures in Italy in the period 2021-2023 was independent from the price of medicines
by: Raffaella Cocciolo, et al.
Published: (2025-01-01)

Valuation of Medical Innovation Handling with Uncertainty and Risk
by: Mark Nuijten, et al.
Published: (2024-08-01)

Drug pricing and reimbursement decision making systems in Mongolia
by: Gereltuya Dorj, et al.
Published: (2017-12-01)

A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01)

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-12-01)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01)

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
by: Goran Medic, et al.
Published: (2017-01-01)

Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
by: Naina R. Verghese, et al.
Published: (2019-01-01)

Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel
by: Claudio Jommi, et al.
Published: (2024-07-01)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
by: Hajer Dahmani, et al.
Published: (2023-12-01)

Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma<sup>®</sup>) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System
by: Rosanna Ruggiero, et al.
Published: (2024-03-01)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
by: David Elvira, et al.
Published: (2023-10-01)

Practice of the Qualification and Recognition for Orphan Drugs in the World and its Inspiration
by: ZHU Xiaohong, et al.
Published: (2022-07-01)

Reimbursement measures in European countries – findings of a bibliometric literature review
by: Sabine Vogler, et al.
Published: (2015-12-01)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)

Rethinking valuation and pricing models : lessons learned from the crisis and future challenges /
by: Wehn, Carsten S., et al.
Published: (2013)

ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION
by: M. V. Sura, et al.
Published: (2015-03-01)

Stock Valuation, Price Earning Ratios, and Firm Performance
by: Osman, Suzana Idayu Wati
Published: (2010)

The short and long run effects of debt-equity ratios and dividend payout ratios on corporation stock prices.
by: White, William L.
Published: (2009)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
by: Xingyue Zhu, et al.
Published: (2023-10-01)

IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM?
by: V. V. Omelyanovskiy
Published: (2015-05-01)

The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change
by: K. E. Young, et al.
Published: (2017-01-01)

Managing new premium-priced medicines in Europe
by: Govin Permanand, et al.
Published: (2015-12-01)

Reimbursement of combined antihypertensive medicenes in Ukraine: aspects of inclusion and external reference pricing
by: A. O. Gonchar, et al.
Published: (2022-12-01)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
by: Andrew L Gray
Published: (2015-12-01)

The impact of level of documentation on the accessibility and affordability of new drugs in Norway
by: Gro Live Fagereng, et al.
Published: (2024-02-01)

Negotiating pricing and payment terms for insurance covered mHealth apps: a qualitative content analysis and taxonomy development based on a German experience
by: Bettina Freitag, et al.
Published: (2024-10-01)

The effect of trans-provincial immediate reimbursement for healthcare expenses on inequity in the utilization of healthcare services for migrants
by: Mei Zhou, et al.
Published: (2024-03-01)

Debates over orphan drug pricing: a meta-narrative literature review
by: Matthew S. Hanchard
Published: (2025-03-01)

Orphan diseases — rare but important!
by: article Editorial
Published: (2019-06-01)

Orphan diseases — rare but important!
by: article Editorial
Published: (2019-06-01)

Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union
by: Bander Balkhi, et al.
Published: (2023-09-01)

COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment
by: Beatrice Canali, et al.
Published: (2023-05-01)